# Moderna, Inc. (MRNA)

Informational only - not investment advice.

CIK: 0001682852
SIC: 2836 Biological Products, (No Diagnostic Substances)
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2836 Biological Products, (No Diagnostic Substances)](/industry/2836/)
Latest 10-K filed: 2026-02-20
SEC page: https://www.sec.gov/edgar/browse/?CIK=1682852
Filing source: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-20 · accession 0001682852-26-000033 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001682852.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 1,944,000,000 USD | 2025 | verified |
| Net income | -2,822,000,000 USD | 2025 | verified |
| Assets | 12,338,000,000 USD | 2025 | verified |
| Free cash flow | -2,065,000,000 USD | 2025 | computed |
| Net margin | -145.16% | 2025 | computed |
| Revenue YoY | -39.93% | 2025 | computed |
| ROE | -32.62% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | MRNA | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -145.2% | -14.7% | 3 | 33 |
| Operating margin | -121.9% | -16.8% | 16 | 32 |
| Revenue growth | -39.9% | 20.9% | 10 | 42 |
| FCF margin | -106.2% | -127.6% | 52 | 43 |
| ROE | -32.6% | -38.7% | 54 | 60 |
| ROA | -22.9% | -30.4% | 66 | 66 |
| Liabilities / equity | 0.43 | 0.38 | 61 | 62 |
| Current ratio | 3.29 | 5.52 | 17 | 66 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2836 Biological Products, (No Diagnostic Substances), not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 1944000000 | USD | 2025 | 2026-02-20 |
| Net income | -2822000000 | USD | 2025 | 2026-02-20 |
| Assets | 12338000000 | USD | 2025 | 2026-02-20 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-20. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001682852.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  |  |  | 60,209,000 |  | 18,471,000,000 | 19,263,000,000 | 6,848,000,000 | 3,236,000,000 | 1,944,000,000 |
| Net income | -216,211,000 | -255,916,000 | -384,734,000 | -514,000,000 | -747,000,000 | 12,202,000,000 | 8,362,000,000 | -4,714,000,000 | -3,561,000,000 | -2,822,000,000 |
| Operating income | -223,771,000 | -269,356,000 | -413,266,000 | -546,000,000 | -763,000,000 | 13,296,000,000 | 9,420,000,000 | -4,239,000,000 | -3,945,000,000 | -3,074,000,000 |
| Diluted EPS |  |  |  | -1.55 | -1.96 | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 |
| Operating cash flow | 66,734,000 | -331,484,000 | -330,865,000 | -459,000,000 | 2,027,000,000 | 13,620,000,000 | 4,981,000,000 | -3,118,000,000 | -3,004,000,000 | -1,873,000,000 |
| Capital expenditures | 33,144,000 | 58,401,000 | 105,766,000 | 32,000,000 | 68,000,000 | 284,000,000 | 400,000,000 | 707,000,000 | 1,051,000,000 | 192,000,000 |
| Share buybacks |  |  |  | 0.00 | 0.00 | 857,000,000 | 3,329,000,000 | 1,153,000,000 | 0.00 | 2,000,000 |
| Assets |  |  | 2,019,962,000 | 1,589,422,000 | 7,337,000,000 | 24,669,000,000 | 25,858,000,000 | 18,426,000,000 | 14,142,000,000 | 12,338,000,000 |
| Liabilities |  |  | 431,908,000 | 414,612,000 | 4,776,000,000 | 10,524,000,000 | 6,735,000,000 | 4,572,000,000 | 3,241,000,000 | 3,688,000,000 |
| Stockholders' equity | -334,810,000 |  | 1,530,000,000 | 1,175,000,000 | 2,561,000,000 | 14,145,000,000 | 19,123,000,000 | 13,854,000,000 | 10,901,000,000 | 8,650,000,000 |
| Cash and cash equivalents | 50,080,000 | 134,859,000 | 658,364,000 | 236,000,000 | 2,624,000,000 | 6,848,000,000 | 3,205,000,000 | 2,907,000,000 | 1,927,000,000 | 2,595,000,000 |
| Free cash flow | 33,590,000 | -389,885,000 | -436,631,000 | -491,000,000 | 1,959,000,000 | 13,336,000,000 | 4,581,000,000 | -3,825,000,000 | -4,055,000,000 | -2,065,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  | 66.06% | 43.41% | -68.84% | -110.04% | -145.16% |
| Operating margin |  |  |  |  |  | 71.98% | 48.90% | -61.90% | -121.91% |  |
| Return on equity |  |  | -25.15% | -43.74% | -29.17% | 86.26% | 43.73% | -34.03% | -32.67% | -32.62% |
| Return on assets |  |  | -19.05% | -32.34% | -10.18% | 49.46% | 32.34% | -25.58% | -25.18% | -22.87% |
| Liabilities / equity |  |  | 0.28 | 0.35 | 1.86 | 0.74 | 0.35 | 0.33 | 0.30 | 0.43 |
| Current ratio |  | 4.09 | 7.02 | 7.89 | 1.43 | 1.76 | 2.73 | 3.42 | 3.67 | 3.29 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-31. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001682852.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 2.53 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.19 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -3.62 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 1,831,000,000 | -3,630,000,000 | -9.53 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 2,811,000,000 | 217,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 167,000,000 | -1,175,000,000 | -3.07 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 241,000,000 | -1,279,000,000 | -3.33 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 1,862,000,000 | 13,000,000 | 0.03 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 966,000,000 | -1,120,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 108,000,000 | -971,000,000 | -2.52 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 142,000,000 | -825,000,000 | -2.13 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 1,016,000,000 | -200,000,000 | -0.51 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 678,000,000 | -826,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 389,000,000 | -1,343,000,000 | -3.40 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 145,000,000 | -782,000,000 | -1.97 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from MRNA's latest 10-K: [/company/MRNA/business/](/company/MRNA/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from MRNA's latest 10-K: [/company/MRNA/risk-factors/](/company/MRNA/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm

Extracted from a later financial-section MD&A body after Item 2 boundaries were low-confidence.
Confidence: high
Filing date: 2026-07-31
Report date: 2026-06-30

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial information and related notes included in this Form 10-Q and our consolidated financial statements and related notes and other financial information in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the SEC) on February 20, 2026 (the 2025 Form 10-K).

Overview

We are a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.

Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We currently have four approved products—Spikevax® and mNEXSPIKE®, our COVID vaccines; mRESVIA®, our vaccine against respiratory syncytial virus (RSV); and mCOMBRIAX®, our flu plus COVID combination vaccine, which was approved in Europe for individuals 50 years of age and older. We also have a diverse development pipeline of 26 development candidates across our 36 development programs currently in clinical studies.

Business Highlights

European Commission Marketing Authorization for mCOMBRIAX

In April 2026, we received marketing authorization from the European Commission (EC) for mCOMBRIAX (mRNA-1083), our mRNA combination vaccine for the prevention of influenza disease and COVID-19 in individuals 50 years of age and older. The marketing authorization follows a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is valid in all 27 European Union (EU) member states, as well as Iceland, Liechtenstein and Norway. mCOMBRIAX is our fourth authorized product and further strengthens our respiratory portfolio and commitment to the EU. The vaccine builds on advances from the clinical development of mNEXSPIKE and mRNA-1010, our investigational seasonal influenza vaccine. mCOMBRIAX will be made available across the EU, subject to national regulatory and access procedures, and we are working with national authorities to support local access and implementation.

FDA Advisory Committee Positive Recommendation for mRNA-1010

In June 2026, the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and in adults 65 years of age and older. The recommendation was based on data from our Phase 3 clinical development program and supports the FDA's ongoing review of our Biologics License Application (BLA) for mRNA-1010. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026.

Expanded Strategic Collaboration with CEPI

In June 2026, we expanded our strategic collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated. Under the agreement, CEPI has committed up to $50 million to support preclinical development and Phase 1 clinical evaluation of our investigational BDBV vaccine candidate, as well as parallel manufacturing activities to enable doses to be produced while clinical evaluation is underway and support rapid advancement into Phase 2/3 clinical trials, if warranted. The program builds on our existing research and development efforts in filoviruses, including Ebola-related viruses, and expands our longstanding strategic collaboration with CEPI to accelerate the development of vaccines and other countermeasures against epidemic and pandemic threats.

Total Revenue and Net Loss Per Share

For the second quarter of 2026, we recognized total revenue of $145 million, compared to $142 million for the second quarter of 2025. Net loss per share was $(1.97) for the second quarter of 2026, compared to net loss per share of $(2.13) for the second quarter of 2025.

29

Table of Contents

Recent Program Developments

Infectious Disease Vaccines

•Seasonal flu + COVID vaccine: We received EC marketing authorization for mCOMBRIAX in the EU and our mRNA-1083 regulatory filings are under review in Japan, Canada and Australia. We are awaiting further guidance from the FDA on refiling the submission for our flu plus COVID combination vaccine.

•Seasonal flu vaccine: Our mRNA-1010 regulatory filings are under review in Europe, Canada and Australia, and potential approvals are expected to begin in 2026. The FDA has assigned a PDUFA date for mRNA-1010 of August 5, 2026.

•Norovirus vaccine: Our Phase 3 safety and efficacy study of mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis. The trial is ongoing and remains blinded as we work toward enrolling an additional cohort.

Oncology Therapeutics

•Intismeran autogene: We are advancing mRNA-4157 in collaboration with Merck, with nine total Phase 2 and Phase 3 clinical trials underway across multiple tumor types, including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. This includes the Phase 3 study of intismeran as monotherapy and in combination with KEYTRUDA QLEX for the treatment of high-risk Stage 1 NSCLC.

Fully enrolled studies include a Phase 3 adjuvant melanoma, a Phase 2 adjuvant renal cell carcinoma, and a Phase 2 adjuvant muscle invasive bladder cancer. We expect Phase 3 adjuvant melanoma data potentially in 2026.

We recently presented positive five-year Phase 2b adjuvant melanoma data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data showed a sustained benefit with intismeran in combination with KEYTRUDA, reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone.

•mRNA-4359. Our Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC.

Rare Disease Therapeutics

•Propionic acidemia (PA) therapeutic: Our investigational therapeutic for PA (mRNA-3927) is in a registrational study and target enrollment has been reached. We expect potential data in 2026.

•Methylmalonic acidemia (MMA) therapeutic: We deferred our decision on a pivotal trial for mRNA-3705 until PA registrational data readout.

30

Table of Contents

Our Pipeline

The following chart shows our current pipeline of 36 development programs across our several modalities.

Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; hMPV, human metapneumovirus; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; NSCLC, non-small cell lung cancer; pCR, pathological complete response; RCC, renal cell carcinoma; RSV, respiratory syncytial virus.

31

Table of Contents

Results of operations

The following table summarizes our condensed consolidated statements of operations for the periods presented (in millions):

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Change 2026 vs. 2025"],["","2026","","2025","","$","","%"],["Revenue:"],["Net product sales","$","94","","","$","114","","","$","(20)","","","(18)%"],["Other revenue","51","","","28","","","23","","","82%"],["Total revenue","145","","","142","","","3","","","2%"],["Operating expenses:"],["Cost of sales","93","","","119","","","(26)","","","(22)%"],["Research and development","651","","","700","","","(49)","","","(7)%"],["Selling, general and administrative","216","","","230","","","(14)","","","(6)%"],["Total operating expenses","960","","","1,049","","","(89)","","","(8)%"],["Loss from operations","(815)","","","(907)","","","92","","","(10)%"],["Interest income","67","","","81","","","(14)","","","(17)%"],["Other (expense) income, net","(19)","","","8","","","(27)","","","(338)%"],["Loss before income taxes","(767)","","","(818)","","","51","","","(6)%"],["Provision for income taxes","15","","","7","","","8","","","114%"],["Net loss","$","(782)","","","$","(825)","","","$","43","","","(5)%"]]
[[/GREPCENT_TABLE]]

[[GREPCENT_TABLE]]
[["","Six Months Ended June 30,","","Change 2026 vs. 2025"],["","2026","","2025","","$","","%"],["Revenue:"],["Net product sales","$","446","","","$","200","","","$","246","","","123%"],["Other revenue","88","","","50","","","38","","","76%"],["Total revenue","534","","","250","","","284","","","114%"],["Operating expenses:"],["Cost of sales","1,048","","","209","","","839","","","401%"],["Research and development","1,300","","","1,556","","","(256)","","","(16)%"],["Selling, general and administrative","389","","","442","","","(53)","","","(12)%"],["Total operating expenses","2,737","","","2,207","","","530","","","24%"],["Loss from operations","(2,203)","","","(1,957)","","","(246)","","","13%"],["Interest income","139","","","171","","","(32)","","","(19)%"],["Other (expense) income, net","(37)","","","4","","","(41)","","","(1,025)%"],["Loss before income taxes","(2,101)","","","(1,782)","","","(319)","","","18%"],["Provision for income taxes","24","","","14","","","10","","","71%"],["Net loss","$","(2,125)","","","$","(1,796)","","","$","(329)","","","18%"]]
[[/GREPCENT_TABLE]]

Revenue

Net product sales

Net product sales by customer geographic location were as follows (in millions):

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Six Months Ended June 30,"],["","","2026","","2025","","2026","","2025"],["United States","","$","70","","","$","88","","","$","143","","","$","119"],["Europe","","16","","","\u2014","","","255","","","\u2014"],["Rest of world","","8","","","26","","","48","","","81"],["Total","","$","94","","","$","114","","","$","446","","","$","200"]]
[[/GREPCENT_TABLE]]

32

Table of Contents

Net product sales by product were as follows (in millions):

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Six Months Ended June 30,"],["","","2026","","2025","","2026","","2025"],["COVID (1)","","$","91","","","$","114","","","$","436","","","$","198"],["RSV","","3","","","\u2014","","","10","","","2"],["Total","","$","94","","","$","114","","","$","446","","","$","200"]]
[[/GREPCENT_TABLE]]

_______

(1) Includes sales of Spikevax and mNEXSPIKE.

As of June 30, 2026, we have four approved products, our COVID vaccines, Spikevax and mNEXSPIKE, our RSV vaccine, mRESVIA, and our flu and COVID combination vaccine, mCOMBRIAX, which has received EC marketing authorization in the EU. We launched commercial sales of mNEXSPIKE in the third quarter of 2025. As of June 30, 2026, mCOMBRIAX had not been commercialized.

We sell our COVID vaccines, Spikevax and mNEXSPIKE, to the commercial market as well as to governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. N

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm
Complete FY 2025 MD&A: /company/MRNA/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-02-20
Report date: 2025-12-31

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in “Part I, Item 1A - Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.

Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We currently have three commercial products—Spikevax® and mNEXSPIKE®, our COVID vaccines, and mRESVIA®, our vaccine against respiratory syncytial virus (RSV). We also have a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies.

2025 Business Highlights

U.S. Manufacturing Capabilities Expansion

In November 2025, we announced the expansion of our U.S. manufacturing capabilities through the onshoring of drug product manufacturing to our existing Moderna Technology Center in Norwood, Massachusetts. Upon completion, this expansion will enable end-to-end mRNA manufacturing in the United States, supporting both commercial and clinical supply needs. This expansion is part of our continued investment in U.S.-based manufacturing infrastructure to support our mRNA vaccine and therapeutic pipeline. Construction for the new drug product manufacturing capability has commenced, with completion targeted in the first half of 2027.

$1.5 Billion Five-Year Credit Facility

In November 2025, we entered into a five-year term loan facility providing for up to $1.5 billion of capital to enhance our balance sheet and provide increased financial flexibility. The facility includes a $600 million initial term loan funded at closing, a $400 million delayed draw term loan facility available through November 2027, and an additional $500 million delayed draw term loan facility available through November 2028, subject to the achievement of specified regulatory milestones.

Total Revenue and Loss Per Share

For the year ended December 31, 2025, we recognized total revenue of $1.9 billion compared to $3.2 billion and $6.8 billion for the years ended December 31, 2024 and 2023, respectively. Loss per share was $(7.26) for the year ended December 31, 2025, compared to loss per share of $(9.28) and $(12.33) for the years ended December 31, 2024 and 2023, respectively.

Program Developments

Infectious Disease Vaccines

•COVID vaccines: We have received approval in 40 countries for our 2025-2026 formula for Spikevax. We have also received U.S. Food and Drug Administration (FDA) approval of our 2025-2026 formula for mNEXSPIKE, our second COVID vaccine, in all adults aged 65 and older, as well as individuals aged 12 to 64 years with at least one underlying risk factor. mNEXSPIKE is also approved in Europe, Canada and Australia and we have filed and are targeting 2026 approvals in Japan and Taiwan.

84

•mRESVIA: Our RSV vaccine has been approved for adults aged 60 years and older in 40 countries. It is also approved in 31 of those countries for individuals 18 to 59 years of age who are at increased risk for disease.

•Seasonal flu vaccine: Our mRNA-1010 regulatory filings are under review in the United States, Europe, Canada and Australia. In February 2026, in response to a prior Refusal-to-File letter, we engaged with the FDA in a Type A meeting and submitted an amended biologics license application (BLA) outlining a revised regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults. Following the meeting and submission of the amended application, the FDA accepted our BLA for review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026.

•Seasonal flu + COVID vaccine: Our mRNA-1083 regulatory filing is under review in Europe and Canada. We are awaiting further guidance from the FDA on refiling.

•Norovirus vaccine: We recently completed enrollment of a second Northern Hemisphere season (2025-2026) cohort in our ongoing Phase 3 study for our norovirus vaccine candidate (mRNA-1403).

Oncology Therapeutics

•Intismeran autogene: We are advancing intismeran (mRNA-4157), our mRNA-based individualized neoantigen therapy, in collaboration with Merck, with eight total Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran in combination with KEYTRUDA, which demonstrated sustained improvement in recurrence-free survival in patients with high-risk melanoma (stage III/IV) following complete resection.

•mRNA-4359: Our Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC, and we expect a potential Phase 2 data readout in 2026.

Rare Disease Therapeutics

•Propionic acidemia (PA) therapeutic: mRNA-3927 is in a registrational study and target enrollment has been reached. In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.

•Methylmalonic acidemia (MMA) therapeutic: mRNA-3705 has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, with a registrational study expected to begin in 2026.

Other Business Updates

During the third quarter of 2025, our mRNA manufacturing facilities in Australia and the United Kingdom were licensed and became operational. These facilities were established under long-term strategic agreements with the respective governments to support domestic mRNA manufacturing and pandemic preparedness. The facilities will enable local supply of our mRNA vaccines and provide rapid response capabilities in the event of future public health emergencies.

In September 2025, we delivered the first mRNA vaccines fully manufactured in Canada from our facility in Laval, Quebec, marking a significant milestone in our collaboration with the Government of Canada. The site, which received its Drug Establishment License from Health Canada in 2024, now produces the drug substance for our updated Spikevax targeting the LP.8.1 variant. Fill-and-finish of the vaccine, including the new single-use pre-filled syringes, is completed by Novocol Pharma in Cambridge, Ontario. This milestone demonstrates the execution of our end-to-end manufacturing strategy and our ability to provide timely access to locally manufactured mRNA vaccines through collaboration with government and industry.

In December 2025, we entered into an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) under which CEPI will provide up to $54 million in funding to support a pivotal Phase 3 clinical trial for our investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, which is expected to begin in early 2026. If licensure is granted and in the event of an influenza pandemic, Moderna is committed to working to provide people around the world with rapid, equitable access to the resulting H5 vaccine, including, as part of this agreement, allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing.

85

Financial Operations Overview

Revenue

Net product sales

Net product sales by customer geographic location were as follows for the periods presented (in millions):

[[GREPCENT_TABLE]]
[["","","","","Years Ended December 31,"],["","","","","","","2025","","2024","","2023"],["United States","","","","","","$","1,165","","","$","1,726","","","$","1,720"],["Europe","","","","","","50","","","573","","","1,353"],["Rest of world","","","","","","603","","","810","","","3,598"],["Total","","","","","","$","1,818","","","$","3,109","","","$","6,671"]]
[[/GREPCENT_TABLE]]

Net product sales by product were as follows (in millions):

[[GREPCENT_TABLE]]
[["","","Years Ended December 31,"],["","","2025","","2024","","2023"],["COVID (1)","","$","1,810","","","$","3,084","","","$","6,671"],["RSV","","8","","","25","","","\u2014"],["Total","","$","1,818","","","$","3,109","","","$","6,671"]]
[[/GREPCENT_TABLE]]

_______

(1)Includes sales of Spikevax and mNEXSPIKE.

As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. We launched commercial sales of mRESVIA in the third quarter of 2024. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.

We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/MRNA/mda/fy2025/
All MD&A years: /company/MRNA/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/MRNA/mda/fy2024/): filed 2025-02-21; accession 0001682852-25-000022 (https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm)
- [FY 2023 MD&A](/company/MRNA/mda/fy2023/): filed 2024-02-23; accession 0001682852-24-000015 (https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/mrna-20231231.htm)
- [FY 2022 MD&A](/company/MRNA/mda/fy2022/): filed 2023-02-24; accession 0001682852-23-000011 (https://www.sec.gov/Archives/edgar/data/1682852/000168285223000011/mrna-20221231.htm)
- [FY 2021 MD&A](/company/MRNA/mda/fy2021/): filed 2022-02-25; accession 0001682852-22-000012 (https://www.sec.gov/Archives/edgar/data/1682852/000168285222000012/mrna-20211231.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2836 Biological Products, (No Diagnostic Substances)) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/MRNA.md · JSON record: /company/MRNA.json · verified financials: /company/MRNA/financials.json / /company/MRNA/financials.csv · machine TOC for the whole site: /llms.txt